---
document_datetime: 2025-12-09 09:53:29
document_pages: 18
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/abecma-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: abecma-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.9731623
conversion_datetime: 2025-12-19 12:53:38.87822
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Abecma

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0058/G            | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.4.b - Change to in-process tests or limits | 27/03/2025                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | applied during the manufacture of the AS - Addition of a new in-process test and limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0060   | B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 20/01/2025 | n/a |
| IB/0056   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 06/01/2025 | n/a |
| IA/0059/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting | 09/12/2024 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                 |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0057           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                              | 22/11/2024 | 22/08/2025 | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/10954 /202403 | Periodic Safety Update EU Single assessment - idecabtagene vicleucel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 31/10/2024 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0047             | - To update section 6.6 of the SmPC - 'Special precautions for disposal and other handling', and corresponding section of the Package Leaflet, to clarify dose preparation and administration instructions of the thawed finished product (IV administration set fitted with a non-leukodepleting in-line filter which can be used to reduce visible cellular aggregates that do not disperse after gentle manual mixing). In addition, the labelling has been updated to include information to appear on the infusion bag - chain of identity label and the package leaflet has been updated to include the local | 19/09/2024 | 22/08/2025 | SmPC, Labelling and PL | Section 6.6 of the SmPC 'Special precautions for disposal and other handling' was updated to clarify the dose preparation, thawing and administration instructions of the thawed finished product. For more information, please refer to the Summary of Product Characteristics. The PL has been updated accordingly. In addition, the labelling has been updated to include information to appear on the infusion bag - chain of identity label and the PL has been updated to include the local representatives of the MAH. |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                             |            |            |                       |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0055           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                | 03/09/2024 | 22/08/2025 | SmPC, Annex II and PL |                                                                                                                                            |
| IB/0054             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                        | 02/08/2024 | n/a        |                       |                                                                                                                                            |
| II/0048             | B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability | 25/07/2024 | n/a        |                       | Not applicable                                                                                                                             |
| IB/0050             | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                       | 11/07/2024 | n/a        |                       |                                                                                                                                            |
| PSUSA/10954 /202309 | Periodic Safety Update EU Single assessment - idecabtagene vicleucel                                                                                                                                          | 25/04/2024 | 20/06/2024 | SmPC, Annex II and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10954/202309. |
| IB/0052             | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                        | 16/05/2024 | n/a        |                       |                                                                                                                                            |
| IB/0051             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure                                                                                                            | 16/05/2024 | n/a        |                       |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                                  |                                                                  |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------|
| IB/0049 | B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15/05/2024 | n/a        |                                  |                                                                  |
| IB/0046 | B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/03/2024 | n/a        |                                  |                                                                  |
| II/0031 | Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD-38 antibody and have demonstrated disease progression on the last therapy for Abecma (idecabtagene vicleucel, ide-cel), based on results from study BB2121-MM-003 (MM-003, KarMMa-3). This is a Phase 3, multicentre, randomised, open-label study to compare the efficacy and safety of ide-cel versus standard regimens in subjects with RRMM. As a consequence, sections 2.1, 2.2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 6.1, 6.3, 6.4 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 3.2 of the RMP has also been submitted. Furthermore, the PI is brought in line with the Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells. | 25/01/2024 | 19/03/2024 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Abecma-H-C-4662-II- 0031' |

<div style=\"page-break-after: always\"></div>

|           | - Change(s) to therapeutic indication(s) - of a new therapeutic indication or of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     | C.I.6.a Addition modification   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------|
| IA/0045/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting | 22/02/2024 | n/a | material/intermediate/reagent   |
| IB/0041   | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 14/12/2023 | n/a |                                 |
| IB/0042   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                 | 07/12/2023 | n/a |                                 |
| IB/0043/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting                                                                                                                                                                                                                                                                                                                                                                                                     | 13/11/2023 | n/a |                                 |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits   |            |            |      |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| PSUSA/10954 /202303 | Periodic Safety Update EU Single assessment - idecabtagene vicleucel                                                                                                                                                                                                                                                                                                                                                             | 26/10/2023 | n/a        |      | PRAC Recommendation - maintenance |
| IA/0040             | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                    | 07/09/2023 | 06/02/2024 | SmPC |                                   |
| IB/0039             | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                                                          | 30/08/2023 | n/a        |      |                                   |
| IB/0038/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                       | 24/08/2023 | n/a        |      |                                   |

<div style=\"page-break-after: always\"></div>

| II/0037/G           | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.3.e - Change in batch size (including batch size                                                       | 20/07/2023   | n/a        |             |                                                                                                                                            |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| II/0034             | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                 | 20/07/2023   | n/a        |             |                                                                                                                                            |
| PSUSA/10954 /202209 | Periodic Safety Update EU Single assessment - idecabtagene vicleucel                                                                                                                                                                                                                                                                                                                                | 26/04/2023   | 23/06/2023 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10954/202209. |
| II/0032/G           | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 22/06/2023   | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting   |            |            |                                                                                                                                                                    |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0035 | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 08/06/2023 | n/a        |                                                                                                                                                                    |
| R/0029  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 26/04/2023 | 08/06/2023 | The CAT and CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     | balance, are of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Abecma, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0033   | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 01/06/2023 | n/a |                                                                                                                                                                                                                                                                                                                          |
| IB/0030/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - | 25/05/2023 | n/a |                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                        |            |     |                      |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------|
| II/0027   | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                 | 26/04/2023 | n/a |                      |
| II/0026   | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol                                                                                                                                                            | 30/03/2023 | n/a |                      |
| II/0022/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 30/03/2023 | n/a | A.4 - Administrative |

<div style=\"page-break-after: always\"></div>

|         | or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS   |            |     | and/or address of a manufacturer   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------|
| IB/0025 | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                            | 30/01/2023 | n/a | procedure                          |
|         | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                                                                                    | 27/01/2023 | n/a | IB/0024/G                          |
| IB/0021 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                              | 16/12/2022 | n/a |                                    |
| II/0020 | B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the                                                                                                                                                                                                | 15/12/2022 | n/a |                                    |

<div style=\"page-break-after: always\"></div>

|                     | AS                                                                                                                                                                                                                                                                                         |            |            |          |                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0019             | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                 | 15/12/2022 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                         |
| PSUSA/10954 /202203 | Periodic Safety Update EU Single assessment - idecabtagene vicleucel                                                                                                                                                                                                                       | 27/10/2022 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0018/G           | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits | 21/09/2022 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0017             | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                     | 24/08/2022 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                         |
| R/0014              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                    | 22/04/2022 | 24/06/2022 | Annex II | The CAT/CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Abecma, subject to the |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                   | Specific Obligations and Conditions as laid down in Annex II to the opinion. The due date for the remaining SOB referring to study KarMMa 3 (MM 003) has been amended due to a protocol amendment of the study occurred since approval of the Conditional Marketing Authorisation for Abecma, which has prolonged the time for the interim analysis and postponed the final clinical study report of about 6 month.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10954 /202109 | Periodic Safety Update EU Single assessment - idecabtagene vicleucel                                                                                                                                                                                                                                                                                                                                   | 05/05/2022 | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0013             | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                | 21/03/2022 | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0015/G           | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 03/03/2022 | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0010             | Update of section 5.1 of the SmPC in order to update efficacy information based on 24 month follow up data from the pivotal study submitted during initial MAA (BB2121-MM-001: A Phase 2, Multicenter Study to determine the Efficacy and Safety of bb2121 in                                                                                                                                          | 27/01/2022 | 24/06/2022 | SmPC and Annex II | Summary Based on the 24 months longer follow-up data regarding MRD-negative status and  CR and duration of responses have been updated in section 5.1 of the SmPC. Specific obligation in the frame of the Conditional Marketing                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           | Subjects with Relapsed and Refractory Multiple Myeloma) listed as a specific obligation in the Annex II and in the RMP; The annex II is updated with the proposed deletion of the relevant SOB. The RMP version 1.2 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                   |            |            |                       | authorisation has been considered fulfilled and deleted from annex II of the product information. For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                              |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002   | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                              | 27/01/2022 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0009   | Update of sections 4.2 and 4.4 of the SmPC, Annex IID and PIL in order to add statements for the use of Abecma exceptionally during shortage of tocilizumab following the \"CAT recommendation for the use of CAR-T cell-based therapies in EU during shortages of tocilizumab\" C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 16/12/2021 | 20/01/2022 | SmPC, Annex II and PL | SmPC new text The product information has been amended to reflect that in the exceptional case where tocilizumab is not available due to a shortage that is listed in the European Medicines Agency shortage catalogue, suitable alternative measures to treat CRS instead of tocilizumab must be available prior to infusion. For more information, please refer to the Summary of Product Characteristics. |
| IB/0012/G | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                   | 17/01/2022 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|           | - Change in the manufacturing process of finished or intermediate product - Other variation - Changes in the manufacturing process of AS - Other variation                                                                                                                                                                                                                                                          |            |            |                        | B.II.b.3.z the B.I.a.2.z the   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------|
| II/0005/G | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting - Other variation | 16/12/2021 | n/a        |                        | material/intermediate/reagent  |
| IB/0008/G | application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other                                                                                                                  | 19/11/2021 | n/a        |                        | This was an variation          |
| T/0007    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                 | 04/11/2021 | 18/11/2021 | SmPC, Labelling and PL |                                |
| IB/0006/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                  | 16/11/2021 | n/a        |                        |                                |

<div style=\"page-break-after: always\"></div>

|             | Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                 |            |            |                                  | B.I.a.2.z -     |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------|
| II/0001/G   | was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a AS | 11/11/2021 | n/a        |                                  | This biological |
| IB/0003     | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                                                 | 05/10/2021 | n/a        |                                  |                 |
| IAIN/0004/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer                                                                                                                                           | 28/09/2021 | 18/11/2021 | SmPC, Annex II, Labelling and PL |                 |

<div style=\"page-break-after: always\"></div>

| responsible for importation and/or batch release -   |
|------------------------------------------------------|
| Not including batch control/testing                  |